CAMBRIDGE, Mass. & NEW YORK–(BUSINESS WIRE)– Foundation Medicine and Memorial Sloan-Kettering Cancer Center today announced a partnership that brings together clinical, genomic and computational expertise to advance patient care in hematologic cancers. This effort will focus on co-development of a new Foundation Medicine molecular diagnostic product designed to match patients with hematologic cancers (leukemia, lymphoma or myeloma) with the most rational targeted therapies or clinical trials for their cancer Continue reading
Tag Archives: clinical-trials
Modernizing Medicine Is Unanimously Voted In as a Member of the Exclusive HIMSS EHR Association
ORLANDO, FL–(Marketwired – Apr 22, 2013) – Partnerships in Clinical Trials — Modernizing Medicine, the creator of the Electronic Medical Assistant (EMA), a cloud-based, specialty-specific electronic medical records (EMR) system, today announced that it has been unanimously voted in as a member of the excusive HIMSS Electronic Health Record (EHR) Association, a trade association of EHR companies addressing national efforts to create interoperable EHRs in hospital and ambulatory care settings. “We welcome Modernizing Medicine to the team and look forward to working with them,” said Mickey McGlynn, EHR Association Chair and Senior Director of Strategy and Operations for Siemens Healthcare.”Every new member brings fresh perspectives and energy to the work we do in representing the industry and our customers on a variety of impactful issues.” Members of the EHR Association work together to accelerate health IT (HIT) adoption, advance interoperability and provide education to all healthcare industry stakeholders including standards organizations and policymakers.Members share the belief that widespread EHR adoption will help improve the quality of patient care and the productivity of the US healthcare system Continue reading
Regenerative Medicine Annual Report Highlights Growth and Promise of Sector, Calls for National Strategy
WASHINGTON, April 17, 2013 /PRNewswire/ — The Regenerative Medicine Annual Report, released today at the Alliance for Regenerative Medicine’s (ARM) first annual Regen Med Investor Day, provides an overview of the tremendous growth and progress in the regenerative medicine (RM) sector during the past year. Continue reading
ACGT Provides Seed Money for T-Cell Immunotherapy Cell and Gene Therapy Research; Successful Clinical Trials for …
ACGT today announced that seed money provided for innovative T-Cell immunotherapy cell and gene therapy research has led to two successful Clinical Trials for treatment of Acute Lymphoblastic Leukemia resulting in remissions in both children and adults who had no other hope of recovery. Stamford, Connecticut (PRWEB) April 08, 2013 According to Michel Sadelain, MD, PhD, ACGT Scientific Advisory Council member and Research Fellow, and senior author of the Acute Lymphoblastic Leukemia study published March 21st in the journal Science Translational Medicine, This is a very exciting finding for patients and a major achievement in the field of targeted immunotherapy. Sadelain explained that these successful treatments would not have been possible had not been for the startup funding from ACGT. Continue reading
Chinese medicine may hold the key to treating diabetes
Traditional Chinese medicine could be a key weapon in the treatment of type 2 diabetes, a joint international study has found. TCM in addition to conventional drugs could be modern medicines best way of treating type 2 diabetes, a joint international study has revealed. Researchers, including The University of Queenslands Dr Sanjoy Paul and Peking Universitys Professor Lilong Ji from Beijing, have found that conventional drugs were significantly more effective when used alongside traditional Chinese medicine in the treatment of type 2 diabetes. Continue reading
Soterix Medical Inc. reports positive results from High-Definition tDCS Fibromyalgia Trial at Harvard Medical School
NEW YORK, Feb. 20, 2013 /PRNewswire/ –Soterix Medical, Inc. is pleased to report positive results of a double-blind, sham-controlled, crossover trial of 18 patients with Fibromyalgia conducted at Harvard Medical School1 Continue reading
Ophthalmology: Gene Therapy Clinical Trials — Katherine Wert, MS – Video
Ophthalmology: Gene Therapy Clinical Trials — Katherine Wert, MS Katherine Wert, Ph.D. Candidate at the Columbia University College of Physicians and Surgeons, discusses the gene therapy clinical trials being run at NewYork-Presbyterian Continue reading
Foundation Medicine Expands Series B Financing to $56 Million
CAMBRIDGE, Mass.–(BUSINESS WIRE)– Foundation Medicine, Inc. Continue reading
Producing Viral Vectors for Clinical Trials With On-Site Clinical Manufacturing Facility – Video
Producing Viral Vectors for Clinical Trials With On-Site Clinical Manufacturing Facility Viral gene therapy is being tested as treatment for numerous diseases, including cancer, cystic fibrosis, heart disease, muscle diseases, diabetes and neurodegenerative disease like Parkinson's. Continue reading
Genetic Engineering Of Mesenchymal Stem Cells – Video
Genetic Engineering Of Mesenchymal Stem Cells ll4.me Genetic Engineering Of Mesenchymal Stem Cells 1. Mesenchymal Stem Cell Engineering and Transplantation: An introduction; F. Aerts, G Continue reading
Five Regenerative Medicine Companies Worthy of Portfolio Addition
Broadly speaking, regenerative medicine is an innovative new area of medicine that is focused on the development of new therapies that enable healing and repair of the body in ways that overcome the limitations of conventional medical treatments. Regenerative medicine uses a range of approaches, including cell based therapies, stem cells, tissue engineering and others, that represent an exciting alternative to traditional pharmaceuticals and current standards of care that, in many cases, still only treat symptoms – as opposed to addressing the underlying cause of the problem whether from disease or injury. In short, regenerative medicine, as the name implies, seeks to repair, regenerate or replace damaged or diseased tissue that is at the root of the problem, in order to restore function and homeostatic health. Continue reading
Researchers Test New Gene Therapy Method in Human Cells… And It Works – Video
Researchers Test New Gene Therapy Method in Human Cells… Continue reading
Gene therapy procedure announced in Oregon could curb hereditary diseases, raise ethical questions
Researchers at Oregon Health & Science University say they have perfected a new gene therapy that could block the transmission of many inherited diseases from mother to child. Continue reading
Digital Medicine at Scripps Health Boosted With $3.75 Million Grant
Digital medicine just got a boost because Scripps Health announced a $3.75 million grant from the Qualcomm Foundation. Some are saying this will help the push to revolutionize healthcare Continue reading
£1.2m EPSRC funding utilised in healthcare nanotechnology
23 July 2012 | By Sam Shead Scientists at Nottingham University are using new funding to engineer nanotechnology that could transform the global healthcare industry. EPSRC funding worth 1.2m will be used as part of a four-year project to develop new ways of manufacturing and scaling up the production of nanoparticles and nanocomposites to be used for drug delivery and bone tissue regeneration Continue reading
Embargoed news from Annals of Internal Medicine
Public release date: 22-Jul-2012 [ | E-mail | Share ] Contact: Abbey Anderson aanderson@acponline.org 215-351-2656 American College of Physicians 1. FDA Panel Members Express Opposing Views on Truvanda Approval In May, the FDA Antiviral Advisory Committee met to review evidence for the approval of two antiretroviral drugs, tenofovir and emtricitabine for pre-exposure prophylaxis (PrEP) against HIV infection. Two members of the Committee explain why they voted for or against the approval. Continue reading
GEN reports on growth of tissue engineering revenues
Public release date: 10-Jul-2012 [ | E-mail | Share ] Contact: John Sterling jsterling@genengnews.com 914-740-2196 Mary Ann Liebert, Inc./Genetic Engineering News New Rochelle, NY, July 9, 2012More than half (52%) of the companies comprising the tissue engineering (TE) and stem cell industries are revenue-generating, compared to about 21% four years ago, reports Genetic Engineering & Biotechnology News (GEN). Of those companies, 31% have commercial products and 21% are service-based; another 30% have products in clinical trials, according to the current issue of GEN. The GEN article is based on interviews with leading tissue engineering researchers and on the findings of a landmark paper (“Progress in the Tissue Engineering and Stem Cell Industry, Are we there yet”), which appears in Tissue Engineering: Part B, Volume 18, Number 3, 2012, published by Mary Ann Liebert, Inc. Continue reading
Health care system or patient-directed programs help prevent or manage diabetes
A new study has found that programs aimed at helping people prevent or manage diabetes are most successful if they are directed at the patient or the health care system. Programs aimed at physicians were only successful for patients with poorer diabetes control Continue reading
New Applications in Drug Discovery Platforms to Fuel Advance of Stem Cells, Says Frost & Sullivan
Ethical, Clinical and Commercial Issues to be Navigated before Full Potential of Stem Cell Therapies can be Unleashed LONDON, June 13, 2012 /PRNewswire-Asia/ — Stem cells offer exciting potential in regenerative medicine, and are likely to be widely used by mid-2017. Continue reading
Research and Markets: Analysis of the Stem Cell Markets-Unlocking the New Era in Therapeutics
DUBLIN–(BUSINESS WIRE)– Research and Markets (http://www.researchandmarkets.com/research/pqrlwc/analysis_of_the_st) has announced the addition of Frost & Sullivan’s new report “Analysis of the Stem Cell Markets-Unlocking the New Era in Therapeutics” to their offering. Continue reading